EaseJect has successfully developed microneedle patch technologies incorporating a broad range of active pharmaceutical ingredients (APIs), spanning from small-molecule drugs to vaccines, across diverse therapeutic indications and physicochemical properties.

The company has recently achieved the successful development of a microneedle patch formulation incorporating cannabidiol (CBD), a highly hydrophobic compound that is practically insoluble in water, demonstrating advanced formulation and delivery capabilities.

In parallel, EaseJect is actively conducting microneedle-based vaccine development projects.
In addition, multiple microneedle patch formulations containing various API classes—previously described—have been successfully developed and have progressed into the biological evaluation and efficacy assessment stage.